Biotech Co.* (Country; Symbol) |
Pharma Co. (Country) |
Product |
Terms/Details (Date) |
| |||
Accelrys Inc. (subsidiary of Pharmacopeia Inc.; PCOP) |
Jubilant Biosys (India) |
Jubilant's ChemBioBase, a database of kinase inhibitors |
Accelrys agreed to be the exclusive distributor of the database, making it a module in its Catalyst 4.9 product suite (12/22) |
|
|||
AEterna Laboratories Inc. (Canada; TSE:AEL) |
Produtos Roche QFSA (Brazilian unit of Roche) |
Deal for the marketing in Brazil of Impavido (miltefosine), an oral therapy for leishmaniasis |
Roche will support AEterna unit Zentaris GmbH in registration efforts in Brazil, and would market the product there; terms were not disclosed (2/2) |
|
|||
Atria Genetics Inc.* |
Abbott Laboratories |
For tests that define human leukocyte antigens used to identify donors for bone marrow transplantation |
Abbott gets exclusive rights outside the U.S. to Atria's AlleleSEQR HLA DNA sequencing-based typing products, and exclusive rights to HLA analyte-specific reagents in the U.S.; terms were not disclosed (1/12) |
|
|||
Atrix Laboratories Inc. (ATRX) |
Han All Pharmaceutical Co. Ltd. (Korea) |
Han All gained distribution rights in Korea to Eligard (leuprolide acetate for injectable suspension) |
Atrix would get royalties on any sales and manufacturing payments; Han All is responsible for all regulatory actions in Korea (1/28) |
|
|||
Auxilium Pharmaceuticals Inc.* |
Bayer Inc. |
Distribution agreement for marketing of Auxilium's Testim 1% testosterone gel in Canada |
Auxilium will file for approval in Canada and Bayer would market the product there; terms were not disclosed (2/2) |
|
|||
BioMarin Pharmaceuticals Inc. (BMRN) |
Merck KGaA (Germany) |
Phenoptin, an enzyme cofactor and second-generation oral form of tetrahydrobiopterin |
Merck subsidiary Merck Eprova AG will manufacture product for clinical trials, which are expected to start in 2004 (11/20) |
|
|||
Cambridge Antibody Technology Group plc (UK; LSE:CAT) |
Lonza Group Ltd. |
Companies extended November 2001 agreement, confirming that Lonza Biologics will manufacture clinical-grade antibodies for CAT through 2006 |
The deal encompasses both ongoing and future products; terms were not disclosed (1/20) |
|
|||
Discovery Laboratories Inc. (DSCO) |
Laureate Pharma LP |
Laureate will provide manu- facturing services to support drugs from Discovery |
As part of the deal Discovery transferred its existing manufacturing equipment to Laureate's microparticle manufacturing facility (1/21) |
|
|||
Diversa Corp. (DVSA) |
BASF Pharma (Germany) |
Enzyme for the biocatalytic synthesis of a pharmaceutical intermediate |
BASF will apply the biocatalyst to one of its processes to synthesize a chiral intermediate; it is the first license taken from their 2002 collaboration; terms were not disclosed (12/1) |
|
|||
Genentech Inc. (NYSE:DNA) |
Lonza Group Ltd. (Switzerland) |
Commercial quantities of Genentech's Rituxan |
Lonza will manufacture product at its facility in Portsmouth, N.H.; terms were not disclosed (12/16) |
|
|||
Hemispherx Biopharma Inc. (AMEX:HEB) |
Fujisawa Deutschland GmbH (Germany) |
Fujisawa got an option to distribute Hemispherx's Ampligen in Germany, Austria and Switzerland |
Fujisawa paid |400,000 for the option and would pay additional undisclosed fees and milestone payments if it exercises the option (2/18) |
|
|||
ID Biomedical Corp.* (Canada) |
Dynport Vaccine Co. |
Second-generation, subunit plague vaccine |
ID is getting about $4.5M in additional funding under their contract for process development and manufacturing activities related to production of a recombinant plague antigen (12/3) |
|
|||
InKine Pharmaceutical Co. Inc. (INKP) |
Pharmatel (Australia) |
Marekting deal for InKine's Visicol in Australia and New Zealand |
Pharmatel paid an undisclosed license fee and will pay royalties to InKine on sales in those countries (1/27) |
|
|||
InKine Pharmaceutical Co. Inc. (INKP) |
Sigma-Tau Pharmaceuticals Inc. |
Co-promotion deal under which InKine will sell Sigma-Tau's VSL#3 in the second position behind Visicol |
InKine could receive $1.5M over the one- year term; additional incentives are built into the deal (12/10) |
|
|||
Inspire Pharmaceuticals Inc. (ISPH) |
Allergan Inc. |
Elestat (epinastine HCL ophthalmic solution 0.05%) in ophthalmic indications |
Allergan will co-promote the product, which was approved in October; Inspire will make an up-front payment and Allergan will pay royalties on sales; they also reworked agreement on Restasis to provide for lower royalties paid to Inspire (12/8) |
|
|||
MediGene AG* (Germany) |
Yamanouchi Pharmaceutical Co. Ltd. (Japan) |
MediGene named Yamanouchi its European marketing partner for the Eligard (Leuprogel) line of prostate cancer products |
MediGene had gained rights from Atrix Laboratories Inc.; terms were not disclosed (1/14) |
|
|||
Nabi Biopharmaceuticals |
Kamada Ltd. (Israel) |
Distribution agreement for Nabi-HB (hepatitis B immune globulin) |
Kamada will coordinate regulatory actions and sell the product in Israel, Argentina, Brazil, Mexico and India (2/6) |
|
|||
NexMed Inc. (NXMD) |
CJ Corp. (South Korea) |
NexMed's Femprox, a cream treatment for female sexual arousal disorder |
CJ will develop and seek approval of the product in Korea, and would pay royalties to NexMed (2/19) |
|
|||
TeGenero AG* (Germany) |
Boehringer Ingelheim GmbH (Germany) |
CD28-SuperMAB (TGN1412), a humanized monoclonal antibody |
BI will be responsible for process development and manufacturing of material for clinical trials (11/17) |
|
|||
Transkaryotic Therapies Inc. (Australia) |
Orphan Australia Fabry's disease |
TKT's Replagal (agalsidase alfa) for the treatment of in Australia and New Zealand for 15 years |
Orphan Australia will have exclusive marketing and distribution rights to Replagal (TKTX) (12/30) |
|
|||
VaxGen Inc. (VXGN) |
Chemo-Sero-Therapeutic Research Institute (Japan) |
Attenuated smallpox vaccine LC16m8 |
VaxGen will purchase vaccine in bulk form and complete secondary manufacture; the deal covers sales in the U.S. but could be expanded (12/2) |
|
|||
| |||
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; LSE = London Stock Exchange.; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange. |